Angela Onwuzoo Fidson Healthcare Plc has announced plans to conduct a Bioequivalence study on the production of chewable formulation of Albendazole tablets in partnership with Liddie BE Limited, a leading clinical research organisation. Albendazole tablet is a worm medication approved by the United States Food and Drug Administration for the treatment of a variety of parasitic worm infections in many parts of the world including Nigeria. The bioequivalence study seeks to improve maternal and child health through access to affordable chewable worm medication.
The founder and Managing Director of Fidson Healthcare Plc, Dr Fidelis Ayebae, who stated this at an event held in Lagos recently, said the bioequivalence study was the first of its kind in the country. Ayebae noted that beyond making the worm tablets more available and affordable, the study also aims to secure World Health Organisation prequalification for the Albendazole tablets manufactured by Fidson. According to him, the study is expected to last 30 days while getting WHO prequalification could take up to 18 months.
Ayebae said, “This partnership is groundbreaking in advancing clinical research, being the first bioequivalence study to be conducted in Nigeria. “We are excited again to be at the forefront of innovation and leadership in the healthcare industry in Nigeria with this landmark effort. This study is a critical step towards the WHO prequalification of our brand of chewable Albendazole tablets.
“This co.